A Phase 3 interventional study of ranibizumab and Laser in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-23.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing ranibizumab in Vision Disorders — none open to participants now, none under way, none of them phase 3. Ranibizumab · Vision Disorders.
Among the 26 studies testing ranibizumab in Vision Disorders, this one is the 11th largest by enrollment, is one of 2 that started in 2010, is one of 14 in phase 3, and was the 6th registered.
361 studies on the registry are indexed under Vision Disorders; 85 are open to participants now.
Browse Vision Disorders studies →None of the 26 studies testing ranibizumab in Vision Disorders is open now. The open studies under Vision Disorders, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 46 Vision Disorders studies recruiting now, 21 (46%) set no upper age limit and 16 (35%) stop at 75 or younger; 18 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 241 is above the median of 75 across 245 interventional studies indexed under Vision Disorders.
Median enrollment 178 across the 26 interventional studies. Of the 22 that completed or were terminated, 19 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 26 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
32 studies in Vision Disorders by Novartis: none open now, none under way, none of them phase 3. Of 30 finished, 25 (83%) have results posted.
Among the 32 studies in Vision Disorders by Novartis, this one is the 15th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2010, is one of 17 in phase 3, and was the 3rd registered.
Novartis’s Vision Disorders studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing ranibizumab in Vision Disorders, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 32 in Vision Disorders:
This tab as a report to print or save as PDF → With an account.
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in comparison with the current standard of care (laser photocoagulation monotherapy), in patients with visual impairment due to DME.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Participants received ranibizumab intravitreal injection and laser photocoagulation treatments
Drug: ranibizumab · Procedure: Laser
Participants received ranibizumab intravitreal injection therapy only
Drug: ranibizumab
Participants received Laser photocoagulation therapy only
Procedure: Laser
Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
Time frame: Baseline and 12 months
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Months 3,6 and 9
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS)is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
Time frame: Baseline, 3, 6 and 9 months
Change From Baseline in Central Retinal Thickness (CRT) at Months 3,6,9 and 12
OCT is a diagnostic imaging technique using low-coherence interferometry to produce cross-sectional tomograms of the posterior segment eye structures. OCT was performed prior to study treatment to assess CRT, presence of fluid in the macula (intra-retinal cyst or fluid) and evaluation of image to monitor disease progression/treatment effect and to determine the need to stop/re-initiate ranibizumab treatment
Time frame: Baseline, 3, 6, 9 and 12 months
Percentage of Patients Achieving a Gain of 15-letters or More (3-lines) in BCVA From Baseline
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A higher percent of patients achieving a gain of ≥15 letters BCVA indicates a better response.
Time frame: Baseline, 3, 6, 9 and 12 months
Percentage of Patients Achieving Gain of Letters From Baseline in BCVA
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A gain of 5,10,15 or more BCVA letters from baseline indicates improvement.
Time frame: 12 months
National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and visual symptoms on general health domains. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each question, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. A composite score for a patient is calculated by aggregating and averaging the scores from the 11 sub-scales (excluding general health sub-scale), and an algorithm is apply to give equal weight to each sub-scale. Sub-scales and composite scores are calculated by converting the response from questionnaires into a 0-100 scale, with 0 as the worst possible outcome and 100 as the best. Missing data was not imputed
Time frame: 12 month
EuroQoL (EQ-5D) Utility Score at Month 12
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain-discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1="no problems", 2="some problems" and 3="extreme problems". Missing values were not imputed. Using the scoring algorithm derived from the Canadian value sets (Bansback et al., 2012), a utility score for a patient was calculated based on the EQ-5D responses for a given time-point at which the questionnaire was presented to the patient. This mean EQ-5D utility score ranged between 0 (worst health) to 1 (perfect health).
Time frame: 12 month
Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12
(TTO) questionnaire was used to help determine the patients' health utility. Reported health utility represents the patients' quality of life at the current health state, and is a cardinal value that ranges from 0 (worst possible health or death) to 1 (best possible health). In this questionnaire, patients were first asked to estimate their remaining life expectancy. Second, the patients were presented with a hypothetical situation where a technology existed that could permanently return their vision to normal. This technology would always work, but would decrease their length of survival. Patients were then asked how much of their remaining life expectancy, if any, they would be willing to trade in return for use of the technology and thus for normal vision. The principle of this measure is that if patients were content with their current vision status (i.e., have a utility value of 1.0), they would not want to trade any of their remaining life years to improve their vision.
Time frame: 12 month
A total of 239 patients were enrolled in the study. An additional 2 patients were enrolled but were removed from the database because consent was not signed in accordance with GCP principles."
| Milestone | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Started | 78 | 80 | 81 |
| Intent to treat (itt) population | 73 | 75 | 72 |
| Safety population | 73 | 75 | 74 |
| Completed | 74 | 75 | 59 |
| Not completed | 4 | 5 | 22 |
| Withdrew: Withdrawal by subject | 1 | 3 | 6 |
| Withdrew: Lost to follow-up | 1 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 3 |
| Withdrew: Lack of efficacy | 2 | 1 | 10 |
| Withdrew: Adverse event | 0 | 1 | 2 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
| Letters | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12 | 8.2 ± 9.20 | 8.9 ± 7.78 | 0.3 ± 12.47 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS)is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.
| Letters | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Month 3 (n=71, 75, 69) | 3.7 ± 10.71 | 5.3 ± 7.58 | 1.4 ± 6.55 |
| Month 6 (n= 70, 72, 65) | 5.6 ± 8.45 | 7.1 ± 7.74 | 0.9 ± 7.23 |
| Month 9 (n=69, 71, 59) | 7.1 ± 7.92 | 6.9 ± 12.45 | -0.2 ± 10.71 |
OCT is a diagnostic imaging technique using low-coherence interferometry to produce cross-sectional tomograms of the posterior segment eye structures. OCT was performed prior to study treatment to assess CRT, presence of fluid in the macula (intra-retinal cyst or fluid) and evaluation of image to monitor disease progression/treatment effect and to determine the need to stop/re-initiate ranibizumab treatment
| um | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Baseline | 422.1 ± 142.26 | 448.5 ± 136.64 | 458.0 ± 133.07 |
| Month 3 (n=71,75, 69) | -105.7 ± 127.74 | -108.9 ± 113.38 | -32.5 ± 114.15 |
| Month 6 (n= 70,72,65) | -114.2 ± 110.88 | -129.3 ± 116.50 | -64.4 ± 110.77 |
| Month 9 (69,70,58) | -138.1 ± 125.86 | -135.9 ± 140.90 | -85.8 ± 128.00 |
| Month 12 (70,71,61) | -152.2 ± 139.27 | -143.5 ± 143.95 | -107.1 ± 143.86 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A higher percent of patients achieving a gain of ≥15 letters BCVA indicates a better response.
| Percentage of Patients | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Month 3 (n=71,75,69) | 8.5 | 9.3 | 2.9 |
| Month 6 (n=70,72,65) | 11.4 | 13.9 | 1.5 |
| Month 9 (69,71,59) | 13.0 | 21.1 | 0 |
| Month 12 (70,71,62) | 24.3 | 21.1 | 6.5 |
Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A gain of 5,10,15 or more BCVA letters from baseline indicates improvement.
| Percentage of Patients | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| 5 letter gain | 61.4 | 70.4 | 40.3 |
| 10 letter gain | 34.3 | 52.1 | 16.1 |
| 15 letter gain | 24.3 | 21.1 | 6.5 |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and visual symptoms on general health domains. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each question, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. A composite score for a patient is calculated by aggregating and averaging the scores from the 11 sub-scales (excluding general health sub-scale), and an algorithm is apply to give equal weight to each sub-scale. Sub-scales and composite scores are calculated by converting the response from questionnaires into a 0-100 scale, with 0 as the worst possible outcome and 100 as the best. Missing data was not imputed
| Units on a Scale | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12 | 85.21 ± 12.77 | 84.29 ± 11.78 | 78.20 ± 17.27 |
The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain-discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1="no problems", 2="some problems" and 3="extreme problems". Missing values were not imputed. Using the scoring algorithm derived from the Canadian value sets (Bansback et al., 2012), a utility score for a patient was calculated based on the EQ-5D responses for a given time-point at which the questionnaire was presented to the patient. This mean EQ-5D utility score ranged between 0 (worst health) to 1 (perfect health).
| Units on a scale | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| EuroQoL (EQ-5D) Utility Score at Month 12 | 0.88 ± 0.15 | 0.88 ± 0.17 | 0.87 ± 0.17 |
(TTO) questionnaire was used to help determine the patients' health utility. Reported health utility represents the patients' quality of life at the current health state, and is a cardinal value that ranges from 0 (worst possible health or death) to 1 (best possible health). In this questionnaire, patients were first asked to estimate their remaining life expectancy. Second, the patients were presented with a hypothetical situation where a technology existed that could permanently return their vision to normal. This technology would always work, but would decrease their length of survival. Patients were then asked how much of their remaining life expectancy, if any, they would be willing to trade in return for use of the technology and thus for normal vision. The principle of this measure is that if patients were content with their current vision status (i.e., have a utility value of 1.0), they would not want to trade any of their remaining life years to improve their vision.
| Units on a scale | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12 | 0.83 ± 0.28 | 0.78 ± 0.23 | 0.80 ± 0.24 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Combination Therapy | — | 9/73 (12.3%) | 26/73 (35.6%) |
| Ranibizumab Monotherapy | — | 10/75 (13.3%) | 26/75 (34.7%) |
| Laser Monotherapy | — | 5/74 (6.8%) | 17/74 (23%) |
| Event | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 0/73 | 0/75 | 2/74 |
| Vitreous haemorrhage (Fellow eye)Eye disorders | 0/73 | 0/75 | 2/74 |
| Vitreous haemorrhage (Study eye)Eye disorders | 0/73 | 0/75 | 2/74 |
| CellulitisInfections and infestations | 0/73 | 2/75 | 0/74 |
| Atrial fibrillationCardiac disorders | 1/73 | 0/75 | 0/74 |
| Colitis ischaemicGastrointestinal disorders | 1/73 | 0/75 | 0/74 |
| Intestinal obstructionGastrointestinal disorders | 1/73 | 0/75 | 0/74 |
| HypothermiaGeneral disorders | 1/73 | 0/75 | 0/74 |
| SarcoidosisImmune system disorders | 1/73 | 0/75 | 0/74 |
| Diabetic foot infectionInfections and infestations | 1/73 | 0/75 | 0/74 |
| Event | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy |
|---|---|---|---|
| Intraocular pressure increased (Study eye)Investigations | 8/73 | 10/75 | 0/74 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 9/73 | 6/75 | 1/74 |
| NasopharyngitisInfections and infestations | 5/73 | 5/75 | 4/74 |
| Neuropathy peripheralNervous system disorders | 5/73 | 1/75 | 0/74 |
| HypertensionVascular disorders | 2/73 | 5/75 | 5/74 |
| Cataract (Fellow eye)Eye disorders | 0/73 | 5/75 | 3/74 |
| Cataract (Study eye)Eye disorders | 0/73 | 5/75 | 0/74 |
| Eye irritation (Study eye)Eye disorders | 4/73 | 0/75 | 0/74 |
| Vision blurred (Study eye)Eye disorders | 4/73 | 0/75 | 0/74 |
| Vitreous haemorrhage (Fellow eye)Eye disorders | 4/73 | 2/75 | 1/74 |
The Intent to Treat (ITT) population was defined as all patients receiving at least one dose of either study treatment for monotherapy treatment arms, or one of the two study treatments for the combination therapy arm, and having at least 1 post-baseline assessment. Patients from a center were excluded from ITT.
| Age, Continuous(years) | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy | Total |
|---|---|---|---|---|
| Mean | 60.8 ± 10.21 | 61.5 ± 9.86 | 62.8 ± 9.44 | 61.7 ± 9.83 |
| Sex: Female, Male(Participants) | Combination Therapy | Ranibizumab Monotherapy | Laser Monotherapy | Total |
|---|---|---|---|---|
| Female | 26 | 33 | 29 | 88 |
| Male | 47 | 42 | 43 | 132 |
The record gives a start of Jul 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab